ATIM-20. A RETROSPECTIVE STUDY EVALUATING THE SAFETY AND SURVIVAL OF THE COMBINATION OF PD-1 IMMUNE CHECKPOINT BLOCKADE AND BEVACIZUMAB IN RECURRENT GLIOBLASTOMA
Joshua Friedman(Icahn School of Medicine at Mount Sinai), Adı́lia Hormigo(Memorial Sloan Kettering Cancer Center)
Cited by 0
Related Papers
Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors
|Neuro-Oncology|2020|44
Quantitative MRI studies for assessment of multiple sclerosis
|Magnetic Resonance in Medicine|1992|43
Tapping into the genome: the role of CSF ctDNA liquid biopsy in glioma
|Neuro-Oncology Advances|2022|28
Quantitative Signal Characteristics of Electrocorticography and Stereoelectroencephalography: The Effect of Contact Depth
|Journal of Clinical Neurophysiology|2019|15
Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy
|British Journal of Haematology|2024|15